2010-03-24 12:04:44
[Go Back]
Business Financial Newswire – Smiths Group says that it diagnostics business, Smiths Detection has signed an agreement whereby Novartis is granted exclusive rights to market Smiths Detection’s Bio-Seeq instrument which enables rapid detection of bacterial and viral pathogens.
Novartis Diagnostics will be responsible for clinical trials, regulatory affairs, sales and marketing.
Financial terms have not been disclosed, but payments will be linked to product development and commercial milestones.
Bill Mawer, President of Smiths Detection Diagnostics, says: “We are delighted that such a major health company as Novartis has chosen to invest in the Bio-Seeq platform and our LATE PCR technology.”
Story provided by Business Financial Newswire
source: http://www.bfnnews.com/display/?id=3807283§ionId=standardNews



Entries (RSS)